论文信息 - Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer. - 字舞流文

Real-World Outcomes of Ribociclib and Aromatase Inhibitor Use in First Line Hormone Receptor Positive, HER2-Negative Metastatic Breast Cancer.

P. Gibbs | E. Lim | S. Lok | D. Tsoi | K. Cuff | R. Blum | K. Clarke | K. Mok | S. Chua | R. D. de Boer | L. Nott | S. Baron-Hay | V. Wong | W. Hong | M. Nottage | Ali M. Tafreshi | A. Uccellini | Michael Green | Frances M. Boyle